Recombinant Sarcophaga bullata FMRFamide-11

What is Sarcophaga bullata and why is it used as a model organism?

Sarcophaga bullata (flesh fly) is widely distributed across North America and serves as an important model organism for studying insect physiology. This species is particularly valuable for examining diapause, development, stress tolerance, neurobiology, and host-parasitoid interactions . The genome of S. bullata has been sequenced, with 15,768 protein-coding genes identified, making it a robust genetic model . This fly is also easy to rear in laboratory settings, which contributes to its utility in various research fields including forensic studies.

What is FMRFamide and what are its basic functions in insects?

FMRFamide (Phe-Met-Arg-Phe-NH2) is a neuropeptide that functions as a neuromodulator across various invertebrate species. In insects and other invertebrates, FMRFamide plays crucial roles in neuroendocrine-immune system (NEIS) functions . Based on research in other invertebrate models, FMRFamide is known to interact with nitric oxide synthase (NOS) and regulate nitric oxide (NO) production, which is involved in immune responses . In some invertebrate species, colocalization of FMRFamide precursor and NOS has been observed, suggesting potential interaction at histological and anatomical levels.

How does recombinant FMRFamide differ from naturally produced FMRFamide?

Recombinant FMRFamide is produced through genetic engineering techniques, typically in bacterial or yeast expression systems, while naturally occurring FMRFamide is synthesized in the organism's neural tissues. The primary advantage of recombinant production is the ability to generate pure, consistent quantities of the peptide for experimental use. The recombinant version should maintain the same amino acid sequence and functional properties, though post-translational modifications present in the natural version may be absent depending on the expression system used.

What are the optimal conditions for expressing recombinant S. bullata FMRFamide-11 in expression systems?

For optimal expression of recombinant S. bullata FMRFamide-11, an E. coli expression system using BL21(DE3) strain with a pET vector containing a His-tag for purification is commonly employed. Expression should be induced with IPTG (0.5-1.0 mM) when culture reaches OD600 of 0.6-0.8, and incubation should continue at 25°C for 4-6 hours to reduce inclusion body formation. Temperature control during expression is critical, as demonstrated in S. bullata experiments where temperature was maintained between 16°C and 18°C for optimal physiological activity .

What purification methods yield the highest purity and recovery of recombinant FMRFamide peptides?

For high-purity recombinant FMRFamide peptides, a multi-step purification protocol is recommended:

• Immobilized metal affinity chromatography (IMAC) using Ni-NTA resin for initial capture of His-tagged peptide

• Size exclusion chromatography to remove aggregates and contaminants

• Reverse-phase HPLC for final polishing and highest purity

Recovery rates typically range from 5-10 mg per liter of bacterial culture, with purity exceeding 95% as verified by SDS-PAGE and mass spectrometry. Maintaining acidic conditions (pH 4.5-5.5) during purification helps prevent peptide degradation.

How can one verify the bioactivity of recombinant S. bullata FMRFamide-11?

Bioactivity verification of recombinant S. bullata FMRFamide-11 can be accomplished through:

• In vitro muscle contraction assays using semi-intact S. bullata larval preparations, measuring isometric force production before and after peptide application

• Nitric oxide production assays in RAW 264.7 cells, as FMRFamide has been shown to inhibit NO production in dose- and time-dependent manners

• Electrophysiological measurements of neuronal activity in S. bullata preparations

• Comparative analysis with commercially available synthetic FMRFamide as a standard reference

A positive control using a known dose-response relationship should be established, where typical effective concentrations range from 10^-9 to 10^-6 M.

What is the relationship between FMRFamide and nitric oxide synthase (NOS) in S. bullata?

While direct evidence specifically for S. bullata is limited in the provided research, studies in other invertebrates suggest that FMRFamide interacts with NOS to regulate NO production. In some species, in situ hybridization has detected colocalization of FMRFamide precursor and NOS-positive signals, suggesting potential interaction at the histological and anatomical levels . RNA interference experiments have shown that when FMRFamide precursor mRNA is knocked down, NOS mRNA is significantly upregulated (at 72h post-knockdown), indicating that FMRFamide likely plays a regulatory role in NO production . This regulatory mechanism is possibly conserved across invertebrates and may function similarly in S. bullata.

How does FMRFamide affect muscle function in S. bullata larvae?

S. bullata larval body wall muscles exhibit neuromuscular hysteresis - a phenomenon where muscle force depends on recent motoneuron activity. In semi-intact preparations, isometric force produced by constant-rate nerve impulses is significantly less than that produced when a brief high-frequency burst of impulses is included . While the direct effect of FMRFamide on this hysteresis has not been explicitly detailed in the provided research, FMRFamide-like peptides generally function as neuromodulators affecting muscle contraction in invertebrates. Research on dipteran muscle indicates that temperature control (16-18°C) is critical for maintaining proper muscle function during experiments , which would be relevant when studying FMRFamide effects on muscle function.

What signaling pathways does FMRFamide activate in immune response regulation?

FMRFamide has been shown to inhibit NO production in immune response models, with administration resulting in significant reduction of NO levels in dose- and time-dependent manners . The inhibitory effect appears to operate through multiple pathways:

• Direct interaction with NOS pathways, potentially reducing NOS activity or expression

• Additional pathways independent of iNOS inhibition, as FMRFamide can further reduce NO production even when iNOS inhibitors are present

• Potential interaction with membrane channels, as suggested by studies with sodium channel inhibitors in other invertebrate models

This inhibitory effect is thought to serve as a feedback regulation mechanism during late stages of immune response, protecting hosts from excessive immune cytotoxicity .

How can recombinant S. bullata FMRFamide-11 be used to study neuroendocrine-immune system interactions?

Recombinant S. bullata FMRFamide-11 can be employed to investigate neuroendocrine-immune system interactions through:

• In vitro macrophage models (e.g., RAW 264.7 cells) challenged with immune stimulants (LPS) to assess how FMRFamide modulates inflammatory responses

• Ex vivo S. bullata hemocyte preparations to analyze direct effects on immune cell function

• RNA-Seq analyses comparing transcriptomic profiles of immune tissues with and without FMRFamide treatment

• CRISPR-Cas9 mediated modification of FMRFamide receptors in S. bullata to create knockout models for analyzing immune function

These approaches can reveal how the neuroendocrine system modulates immune responses, providing insights into evolutionary conservation of these regulatory mechanisms across invertebrates.

What methodological approaches are recommended for studying FMRFamide receptor interactions in S. bullata?

For studying FMRFamide receptor interactions in S. bullata, the following methodological approaches are recommended:

• Receptor binding assays: Using tritium or fluorophore-labeled recombinant FMRFamide-11 to quantify receptor binding in membrane preparations

• GPCR activation assays: Measuring second messenger (cAMP, Ca²⁺) responses in cells expressing cloned S. bullata FMRFamide receptors

• Electrophysiological recordings: Patch-clamp techniques on neurons or muscle cells before and after peptide application

• RNA interference: Knockdown of potential receptor candidates followed by functional assays to confirm receptor identity

• Transcriptomic analysis: RNA-Seq of S. bullata tissues to identify differential gene expression after FMRFamide treatment

Based on genome and RNA-Seq analyses of S. bullata, 15,768 protein-coding genes have been identified , facilitating targeted approaches to receptor identification.

How can developmental stage-specific effects of FMRFamide be investigated in S. bullata?

Investigating developmental stage-specific effects of FMRFamide in S. bullata requires a comprehensive approach:

• Developmental RNA-Seq profiling: Analysis of FMRFamide receptor expression across different developmental stages including larvae, pupae (3-day), and adult males and females

• Stage-specific functional assays: Comparison of FMRFamide effects on muscle contraction, NO production, and stress responses across developmental stages

• Immunohistochemical mapping: Spatial distribution analysis of FMRFamide receptors during development

• Conditional gene expression systems: Creation of transgenic lines with stage-specific receptor knockdown or overexpression

Gene expression analyses from S. bullata genome studies have already identified stage and sex-specific gene sets, with 871 genes differentially expressed between males, females, larvae, and pupae . This existing data provides a foundation for investigating stage-specific FMRFamide effects.

How do the effects of FMRFamide differ between S. bullata and other dipteran species?

Comparative studies between S. bullata and other dipteran species (such as Drosophila melanogaster) reveal both similarities and differences in FMRFamide effects:

• Both species show neuromuscular hysteresis in larval body wall muscles, but species-specific differences in magnitude may exist

• Genome analysis reveals S. bullata has 15,768 protein-coding genes, which may include unique FMRFamide-responsive genes not found in Drosophila

• Developmental timing of FMRFamide sensitivity likely differs due to S. bullata's larviparous reproduction (females give birth to active first instar larvae rather than eggs)

These comparative approaches help identify conserved mechanisms versus species-specific adaptations in neuropeptide signaling across dipteran insects.

What are the evolutionary implications of FMRFamide signaling conservation across invertebrates?

The conservation of FMRFamide signaling across invertebrates has significant evolutionary implications:

• FMRFamide's regulatory role in NO production during immune responses appears to be an ancient mechanism conserved across phylogenetically distant invertebrates

• The dual function in neuromuscular control and immune regulation suggests early evolutionary integration of neural and immune systems

• Comparative genomic analyses between S. bullata and other invertebrates can reveal the evolutionary history of this signaling pathway

• Species-specific adaptations in FMRFamide signaling may reflect ecological niche specialization

The study of FMRFamide signaling in S. bullata and comparison with other invertebrates provides insights into the evolution of neuroendocrine-immune system interactions across animal phyla.

How can recombinant S. bullata FMRFamide-11 be used to investigate stress tolerance mechanisms?

Recombinant S. bullata FMRFamide-11 offers valuable approaches to investigate stress tolerance mechanisms:

• Thermal stress experiments: Measuring survival rates and heat shock protein expression in S. bullata exposed to temperature extremes with and without FMRFamide treatment

• Hypoxia tolerance assays: Assessing the role of FMRFamide in modulating responses to low oxygen conditions, particularly relevant given S. bullata larvae's natural exposure to anoxic carrion environments

• Oxidative stress models: Quantifying reactive oxygen species and antioxidant enzyme activities after FMRFamide treatment under oxidative challenges

• Multi-omics approach: Combining transcriptomics, proteomics, and metabolomics to create comprehensive profiles of FMRFamide-mediated stress responses

S. bullata's natural adaptation to stressful environments (temperature extremes, pathogens, anoxia) makes it an excellent model for studying neuropeptide-mediated stress tolerance mechanisms .

How can researchers overcome stability issues with recombinant FMRFamide peptides?

Researchers can address stability issues with recombinant FMRFamide peptides through:

• Buffer optimization: Using acidic buffers (pH 4.5-5.5) with 5-10% glycerol to prevent aggregation and degradation

• Storage protocols: Lyophilization or storage in single-use aliquots at -80°C with minimal freeze-thaw cycles

• Chemical modifications: C-terminal amidation and N-terminal acetylation to mimic natural post-translational modifications and enhance stability

• Carrier proteins: Fusion with carrier proteins (like thioredoxin) during expression to enhance solubility, with subsequent cleavage during purification

• Cyclization techniques: Creating cyclic peptide derivatives with enhanced stability while maintaining biological activity

Monitoring stability through regular HPLC and mass spectrometry analyses is recommended, with typical shelf-life ranging from 6-12 months under optimal storage conditions.

What controls and validation steps are essential when using recombinant FMRFamide in experimental setups?

Essential controls and validation steps for recombinant FMRFamide experiments include:

• Peptide sequence verification: Mass spectrometry confirmation of peptide identity and purity (>95%)

• Activity controls: Comparison with synthetic FMRFamide peptide in standardized bioassays

• Negative controls: Experiments using scrambled peptide sequences or heat-inactivated peptide

• Receptor antagonist controls: Application of known FMRFamide receptor blockers to confirm specificity of observed effects

• Dose-response validation: Testing multiple concentrations (typically 10^-10 to 10^-6 M) to establish EC50 values

• Cross-contamination prevention: Regular testing for endotoxin contamination in recombinant preparations

• Inter-batch consistency: Statistical comparison between experimental results from different peptide preparations

Temperature control during experiments is particularly important, as demonstrated in S. bullata studies where temperature was maintained between 16-18°C via recirculation of coolant through the preparation stage .

How can the efficiency of recombinant FMRFamide production be optimized for long-term research projects?

For long-term research projects requiring consistent recombinant FMRFamide supplies, optimization strategies include:

• Expression system selection: Comparing yields between bacterial (E. coli), yeast (P. pastoris), and insect cell (Sf9) expression systems to identify optimal production platform

• Codon optimization: Customizing codon usage in the expression construct for the host organism to enhance translation efficiency

• Scale-up parameters: Establishing bioreactor cultivation protocols with defined feed strategies and induction timing

• Automated purification: Implementing FPLC-based purification with standardized protocols to ensure batch-to-batch consistency

• Quality control pipeline: Developing routine analytical methods (HPLC, mass spectrometry, bioactivity assays) for rapid batch verification

• Long-term storage solutions: Validating stability under various storage conditions (lyophilized vs. solution, -20°C vs. -80°C)

Typical optimization can increase yields from 5-10 mg/L to 20-30 mg/L of culture while maintaining >95% purity and full bioactivity.